Qilu Pharmaceutical Co., Ltd. (Dongjia Site) – FDA 483, May 24, 2024
An FDA inspection of Qilu Pharmaceutical Co., Ltd. (Dongjia Site) in Jinan, China, revealed significant deficiencies in their aseptic manufacturing operations. Observations included a lack of established procedures for preventing microbiological contamination, inadequate cleaning and maintenance protocols for equipment, and incomplete master production and control records. Additionally, the firm failed to properly qualify production equipment, raising concerns about the sterility and quality of their drug products.
ID · b02ec5dd-7ed6-4bb1-93cb-44e68316c45f
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.